earnings
confidence high
sentiment positive
materiality 0.55
Graphite Bio doses first SCD patient with nula-cel; Q2 net loss $25.9M, cash $328.3M
LENZ Therapeutics, Inc.
2022-Q2 EPS reported
-$0.95
- Dosed first patient in Phase 1/2 CEDAR trial of nula-cel for sickle cell disease; initial proof-of-concept data expected mid-2023.
- Cash, cash equivalents and marketable securities of $328.3M as of June 30, 2022; cash runway into Q4 2024.
- Q2 2022 net loss of $25.9M ($0.48 per share); R&D expenses $17.8M, G&A $9.0M.
- Nula-cel received FDA Fast Track designation for SCD; also has Orphan Drug designation.
- Preclinical data for GPH102 in beta-thalassemia presented at ASGCT; IND planned by mid-2024.